A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Phase 2 Completed 430 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety/tolerability of 3 different dosages of JNJ-31001074 compared with placebo in adult patients with attention-deficit/hyperactivity disorder (ADHD).

Timeline

Start: 2009-05
Primary completion: 2010-01
Completion: 2010-01

Publications

Weisler RH, Pandina GJ, Daly EJ, Cooper K, Gassmann-Mayer C; 31001074-ATT2001 Study Investigators. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs. 2012 May 1;26(5):421-34. doi: 10.2165/11631990-000000000-00000.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Atomoxetine	Other / unclassified	80 mg	Oral
Comparator	Methylphenidate	Small molecule	54 mg	Oral
Subject	bavisant	Small molecule	1 mg	Oral
Subject	bavisant	Small molecule	3 mg	Oral
Subject	bavisant	Small molecule	10 mg	Oral

A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Summary

Timeline

Publications

Drugs

Indications